Unlock stock picks and a broker-level newsfeed that powers Wall Street.

Odysight.ai Reports Financial Results for the Nine Months Ended September 30, 2024 and Provides Business Update

In This Article:

Odysight.ai Inc.
Odysight.ai Inc.

OMER, Israel, Nov. 14, 2024 (GLOBE NEWSWIRE) -- Odysight.ai Inc. (OTCQB: ODYS), a leading provider of visual based predictive maintenance (PdM) and condition-based monitoring (CBM) solutions, announced its 2024 nine months financial results and provided a business update.

Key highlights

Revenue for the nine months of 2024 was approximately $2.7 million; Cash Balance1 of approximately $21.2 million as of September 30, 2024
--
Backlog reached a record high of approximately $16 million
--
Raised $10.3 million in private placement during July to accelerate growth, while targeting Nasdaq uplisting

--

Signed purchase order agreement exceeding $10 million with a leading international defense contractor, to be fully integrated in its selected UAV lines
--
Purchase orders received for the Israel Air Force (IAF) Boeing AH-64 Apache attack helicopter prototype and from an international defense contractor for PdM system, to be installed in upgraded IAF maritime version SH-60 Seahawk
--
Repeat purchase order from NASA for its comprehensive visualization solution, to support its high-speed aeronautical flight testing
--
Purchase orders received from France-based Safran aircraft engines and from Tel Aviv University on behalf of the Israel Ministry of Defense for a bespoke system based on proprietary visual sensors
--

Einav Brenner, Odysight.ai's Chief Financial Officer, said"We are thrilled by the growing recognition Odysight.ai is receiving from blue-chip global aerospace industry leaders. We continue to improve our financial performance, as reflected by the significant signed agreement exceeding $10 million and our backlog level.

Financial highlights for the nine months ended September 30, 2024 (Unaudited)

Revenues for the nine months ended September 30, 2024, were approximately $2.7 million, compared to $1.1 million for the nine months ended September 30, 2023, an increase of approximately 145%. The increase is primarily attributable to a higher unit sale price, a growing number of units sold to a Fortune 500 multinational healthcare corporation, as well as Industry 4.0 related revenues.

Cost of Revenues for the nine months ended September 30, 2024 was $2.0 million, compared to $1.6 million for the nine months ended September 30, 2023, an increase of approximately 19%. The increase is primarily attributable to the costs associated with the increase in the number of units sold.

Gross Profit for the nine months ended September 30, 2024 was $0.7 million, compared to gross loss of $0.6 million for the nine months ended September 30, 2023. The transition to gross profit is attributable to both revenue growth as well as the decrease in cost of revenues.